When did Phathom Pharmaceuticals, Inc. report Q4 2024 earnings?

Phathom Pharmaceuticals, Inc. (PHAT) reported Q4 2024 earnings on March 6, 2025 before market open.

What were Phathom Pharmaceuticals, Inc.'s Q4 2024 revenue and EPS?

Phathom Pharmaceuticals, Inc. reported revenue of $29.7M and eps of $-0.79 for Q4 2024.

Did Phathom Pharmaceuticals, Inc. beat estimates in Q4 2024?

Revenue beat the consensus estimate of $29.0M by $625.5K. EPS beat the consensus estimate of $-1.29 by $0.50.

Where can I find Phathom Pharmaceuticals, Inc.'s Q4 2024 SEC filings?

You can read the 10-K periodic report (0000950170-25-034183) directly on SEC EDGAR. The filing index links above go to sec.gov.

Phathom Pharmaceuticals, Inc. PHAT Q4 2024 Annual earnings

Reported March 6, 2025 · Before market open

Revenue$29.7MBeat by $625.5K

EPS-$0.79Beat by $0.50

Revenue estimate$29.0M

EPS estimate-$1.29

Next report

Jul 30, 2026 (Tomorrow)

Revenue estimate$72.7M

EPS estimate-$0.06

Financials

Q4 2024

Income statement

See full

Revenue$29.7M+4,250%

Gross profit$25.8M+4,919%

Operating income-$59.4M+15.0%

Net income-$74.5M+6.4%

EPS (diluted)-$1.00+31.0%

Balance sheet

See full

Cash & equivalents$297.3M-22.1%

Total debt$201.9M+45.2%

Total equity-$253.6M-249%

Total assets$378.3M-8.6%

Cash flow

See full

Operating cash flow-$63.5M-44.9%

CapEx$5.0K-98.9%

Free cash flow-$63.5M-43.3%

Valuation & ratios

Valuation

as of 12/31/24

See full

Market cap$555.22M+6.1%

Enterprise value$459.87M+63.8%

P/S10×-757×

Profitability

See full

Gross margin85.6%+10.1pp

Operating margin-502.2%-248pp

Net margin-605.1%-299pp

FCF margin-483.1%-239pp

Returns & leverage

See full

Current ratio4.2×-6.0×

Segments

By segment

See full

Reportable Segment Aggregation Before Other Operating$29.7M+17,298%

By product

See full

Voquezna Product$29.7M+4,143%

Versus estimates

Revenue

Q1 2026$58.3MBeat by $2.4M Q4 2025$57.6MBeat by $412.4K Q3 2025$49.5MMiss by $7.9M Q2 2025$39.5MMiss by $7.3M Q1 2025$28.5MMiss by $7.1M

Q4 2024$29.7MBeat by $625.5K

Diluted EPS

Q1 2026-$0.37Miss by $0.10 Q4 2025-$0.16Beat by $0.16 Q3 2025-$0.15Beat by $0.15 Q2 2025-$0.79Miss by $0.03 Q1 2025-$1.07Miss by $0.01

Q4 2024-$0.79Beat by $0.50

Ask the moment Phathom Pharmaceuticals, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI

Claude

Questions, answered.

When did Phathom Pharmaceuticals, Inc. report Q4 2024 earnings?: Phathom Pharmaceuticals, Inc. (PHAT) reported Q4 2024 earnings on March 6, 2025 before market open.
What were Phathom Pharmaceuticals, Inc.'s Q4 2024 revenue and EPS?: Phathom Pharmaceuticals, Inc. reported revenue of $29.7M and eps of $-0.79 for Q4 2024.
Did Phathom Pharmaceuticals, Inc. beat estimates in Q4 2024?: Revenue beat the consensus estimate of $29.0M by $625.5K. EPS beat the consensus estimate of $-1.29 by $0.50.
Where can I find Phathom Pharmaceuticals, Inc.'s Q4 2024 SEC filings?: You can read the 10-K periodic report (0000950170-25-034183) directly on SEC EDGAR. The filing index links above go to sec.gov.